CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 720 enrolled
Drug / intervention
PF-00299804 +1 moredrug
Likely dose
PF-00299804 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01000025
NCT01000025Phase 3Completed
CompareCT.gov

A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease

NCIC Clinical Trials Group·interventional·Posted Oct 22, 2009·Updated Aug 22, 2023

In Brief

A Phase 3 clinical trial evaluating PF-00299804 and Placebo for Lung Cancer. Completed, enrolled 720 participants across 89 sites in 12 countries.

Detailed Summary

RATIONALE: PF-00299804 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether PF-00299804 is more effective than a placebo in treating patients with advanced non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying PF-00299804 to see how well it works compared with a placebo in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to standard therapy for advanced or metastatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesArgentina, Australia, Brazil, Canada, Italy, New Zealand, Peru, Philippines, South Korea, Taiwan, Thailand, United States
CollaboratorsPfizer

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 22, 2009
Enrollment StartDec 23, 2009
Primary CompletionJan 15, 2014
Study CompletionNov 27, 2015
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 16.7 years ago

Interventions

PF-00299804drug

PF-804 45 mg PO, daily

Placebodrug

Placebo 45 mg PO, daily